ALGS Q1 2022 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+182.5% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$36M-1383.0% margin

Net Income

-$36M-1385.3% margin

EPS (Diluted)

$-0.84

QoQ Revenue Growth

+600.5%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$210M

Total Liabilities

$58M

Stockholders' Equity

$153M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$910,000	+182.5%
Gross Profit	$3M	$910,000	+182.5%
Operating Income	-$36M	-$28M	-28.2%
Net Income	-$36M	-$28M	-28.7%